Ghesquières, Hervé
Rossi, Cédric
Cherblanc, Fanny
Le Guyader-Peyrou, Sandra
Bijou, Fontanet
Sujobert, Pierre
Fabbro-Peray, Pascale
Bernier, Adeline
Belot, Aurélien
Chartier, Loic
Fornecker, Luc-Matthieu
Baldi, Isabelle
Bouabdallah, Krimo
Laurent, Camille
Oberic, Lucie
Morineau, Nadine
Le Gouill, Steven
Morschhauser, Franck
Haioun, Corinne
Damaj, Gandhi
Guidez, Stéphanie
Labouré, Gaëlle
Fitoussi, Olivier
Lebras, Laure
Gressin, Rémy
Salles, Gilles
Ysebaert, Loïc
Monnereau, Alain
Funding for this research was provided by:
Roche (NA)
Celgene International II SARL (NA)
Takeda France SAS (NA)
Janssen-Cilag (NA)
Amgen SAS (NA)
Article History
Received: 6 October 2020
Accepted: 12 February 2021
First Online: 2 March 2021
Ethics approval and consent to participate
: The study is performed according to the declaration of Helsinki, and national laws and regulations for RIPH2 studies. The REALYSA study was approved by a French ethics committee (CPP Ouest II – file number: 2018/46) and by the National Commission for data protection and freedom of information (CNIL – decision number: DR-2018-238)). Written informed consent is obtained from patients before any data collection. A specific signed consent form is also obtained from each patient willing to participate to genetic studies that may be conducted on blood samples. Patients are free to refuse to participate, or to withdraw from the study at any time. Collected data are anonymous and secure data management systems are used. Any substantial change of the protocol (e.g. number of centers, number of collected blood samples) will be validated by the ethics committee before implementation.
: Not applicable.
: The authors declare that they have no competing interests. The study is currently funded by several commercial organizations (Roche, Takeda, Janssen, Amgen, Celgene).